Troxerutin Velpharm capsules 300mg, 60pcs

Composition

Per capsule:

Active ingredient: troxerutin-300 mg.

Auxiliary substances: macrogol 6000 (polyethylene glycol 6000, polyethylene oxide 6000), magnesium stearate.

Composition of the gelatin capsule: body: titanium dioxide, gelatin; cap: dye sunset yellow, dye quinoline yellow, titanium dioxide, gelatin.

Pharmacological action

Pharmacotherapeutic group: venotonizing and venoprotective agent.

ATX code: C 05 CA 04.

Pharmacological properties

Pharmacodynamics

Semi-synthetic bioflavonoid (rutin derivative) of the benzopyran class, has P-vitamin activity, has venotonizing, angioprotective, anti-inflammatory and anti-edematous effects, reduces capillary permeability and fragility.

Its pharmacodynamic properties are associated with the involvement of the bioflavonoids troxerutin in redox processes and inhibition of hyaluronidase. By inhibiting hyaluronidase, troxerutin stabilizes the hyaluronic acid of cell membranes and reduces their permeability. It has antioxidant activity, as a result of which it prevents the oxidation of ascorbic acid, epinephrine and lipids. In addition, it reduces the permeability and fragility of capillaries, prevents damage to the basement membrane of endothelial cells when exposed to various factors. Troxerutin increases the density of the vascular wall, reduces the exudation of the liquid part of the plasma and blood cell diapedesis. Reduces exudative inflammation in the vascular wall, reducing platelet adhesion to its surface. Inhibits aggregation and increases the degree of deformation of red blood cells.

The use of troxerutin is possible, both at the initial and late stages of treatment of chronic venous insufficiency, it can be used as one of the components of complex treatment. Troxerutin reduces swelling and heaviness in the legs, reduces the intensity of pain and cramps, and improves tissue trophism.

Troxerutin relieves the symptoms associated with hemorrhoids (pain, exudation, itching, bleeding).

Troxerutin helps slow the progression of diabetic retinopathy due to its effect on the permeability and resistance of capillary walls.

The effect of troxerutin on the rheological properties of blood helps prevent the development of retinal vascular microthrombosis.

Pharmacokinetics

Troxerutin is rapidly absorbed when the drug is taken orally. The maximum concentration of troxerutin in blood plasma (Cmax) is established on average in 1.75 ± 0.46 hours after oral use. Absorption is approximately 10-15%. The bioavailability of the drug increases with increasing dose. The elimination half-life (T 1/2) is 6.77 ± 2.37 hours. The therapeutic concentration of the drug in the blood plasma is maintained for

8 hours. 30 hours after taking troxerutin, the second maximum concentration of the drug in blood plasma is observed, due to enterohepatic recirculation. Partially metabolized in the liver to form glucuronide and trihydroethylquercitin. It is mainly excreted through the intestines (up to 65-70%), a smaller part (up to 25%) of the drug is excreted unchanged by the kidneys.

Indications

– varicose veins;

chronic venous insufficiency with such manifestations as heaviness in the legs, trophic lesions of the skin (dermatitis, trophic ulcers);

– superficial thrombophlebitis, periflebit;

hemorrhoids;

– post-thrombotic syndrome;

post – traumatic edema, hematoma;

– prevention of complications after sclerotherapy and/or removal of varicose veins of the lower extremities;

in the complex treatment of retinopathy in patients with diabetes mellitus, arterial hypertension and atherosclerosis.

Use during pregnancy and lactation

The use of the drug during the first trimester of pregnancy is contraindicated. The possibility of using the drug during the second and third trimesters of pregnancy is determined by the doctor and is possible only if the intended benefit to the mother exceeds the potential risk to the fetus.

If it is necessary to use the drug in the second and third trimesters of pregnancy, you should consult your doctor.

There are no data on the penetration of troxerutin into breast milk. The use of the drug during breastfeeding is contraindicated.

Contraindications

-hypersensitivity to troxerutin and other components of the drug;

– peptic ulcer of the stomach, duodenum, chronic gastritis in the acute phase;

– pregnancy (I trimester);

– breastfeeding;

– children under 18 years of age (experience with the drug is limited).

With caution

In patients with chronic renal failure (with prolonged use).

Side effects

Troxerutin is very well tolerated, with mild adverse reactions occurring in rare cases.

Immune system disorders: hypersensitivity reactions.

Nervous system disorders: headache.

Vascular disorders: “hot flashes” of blood to the face.

Gastrointestinal disorders: nausea, vomiting, stomach pain, flatulence, diarrhea, erosive and ulcerative lesions of the gastrointestinal tract.

Skin and subcutaneous tissue disorders: erythema, pruritus, skin rash.

If any of the side effects listed in the instructions get worse or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

When used simultaneously, it enhances the effect of ascorbic acid on resistance and permeability of the vascular wall.

How to take, course of use and dosage

The drug is taken orally, with meals. Capsules should be swallowed whole, washed down with a sufficient amount of water.

At the initial stage of treatment,1 capsule (300 mg) is prescribed 3 times a day. The effect usually develops within 2 weeks. Further, treatment is continued at the same dose or reduced to the average therapeutic dose-1 capsule 2 times a day (600 mg), or suspended (while the achieved effect persists for at least 4 weeks). If necessary, the dose can be increased after consulting your doctor. The average course of treatment is 3-4 weeks.

For maintenance therapy, it is sufficient to take 1 capsule (300 mg) per day for 3 to 4 weeks.

With diabetic retinopathy, the drug is used 0.9-1.8 g per day, this corresponds to taking 1-2 capsules three times a day. The average course of treatment is 3-4 weeks.

The need for longer treatment is determined after consultation with a doctor and individually.

Overdose

In case of overdose, you should immediately consult a doctor.

Troxerutin has very low toxicity. In case of overdose, the following symptoms may occur: agitation, nausea, headache, “flushes” of blood to the face.

Treatment: it is necessary to wash the stomach, take activated charcoal (within an hour after ingestion), consult a doctor, if necessary, conduct symptomatic and supportive treatment.

Description

Solid gelatin capsules No. 1 with a white body and a yellow cap. The contents of the capsule range from greenish-yellow or yellow to yellow-green or yellow-brown in the form of powder with various particle sizes and granules, or powder compressed into cylinders that disintegrate when pressed.

Special instructions

Experience of using the drug in children under the age of 18 years is insufficient.

In the treatment of superficial thrombophlebitis or deep vein thrombosis, the use of the drug does not exclude the need to prescribe anti-inflammatory and antithrombotic therapy.

Troxerutin is ineffective for edema caused by concomitant diseases of the liver, kidneys and heart.

When using the drug independently, the maximum time and recommended doses should not be exceeded.

If the severity of the symptoms of the disease does not decrease or the symptoms of the disease become more severe during the use of the drug, you should immediately consult a doctor.

Influence on the ability to drive vehicles and mechanisms

Taking the drug does not affect motor and mental reactions, does not interfere with driving vehicles and other complex mechanisms.

Storage conditions

Store at a temperature not exceeding 25 °C. Keep out of reach of children.

Shelf

life is 3 years.

Do not use after the expiration date.

Active ingredient

Troxerutin

Dosage form

Capsules

Purpose

For adults, Pregnant women in the second and third trimester as prescribed by a doctor

Indications

Vascular lesions in diabetes mellitus, Thrombophlebitis, Swelling after injuries and operations, Varicose veins, Vascular eye diseases, Hemorrhoids